中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2015年
22期
3-5
,共3页
三七皂甙%阿司匹林%脑梗塞%临床疗效%药物安全性
三七皂甙%阿司匹林%腦梗塞%臨床療效%藥物安全性
삼칠조대%아사필림%뇌경새%림상료효%약물안전성
Arasaponin%Acetylsalicylic acid%Cerebral infarction%Clinical efficacy%Safety of medicine
目的：探讨三七皂甙联合阿司匹林治疗脑梗塞的临床疗效及安全性。方法：将84例临床诊断为脑梗塞的中老年患者随机分为3组，其中阿司匹林组29例，口服拜阿司匹灵；三七皂甙组27例，口服三七通舒胶囊；三七皂甙联合阿司匹林组28例，联合服用拜阿司匹灵和三七通舒胶囊。比较三组患者的临床疗效，并分析药物安全性。结果：三组患者治疗后神经功能缺损积分与治疗前相比，均显著降低（P<0.01）。III组与I组和II组相比，积分降低显著（P<0.05）。与I组相比，II组、III组PT明显延长，且较I组效果显著（P<0.01）。在PT-INR比较中，三组患者PT-INR均呈现升高的趋势（P<0.01），其中以III组效果最佳，与I组和II组相比有显著性差异（P<0.01）。三组治疗后 D-D、PAgT 水平均明显下降（P<0.01）。I 组患者 PAgT 水平优于 II 组（P<0.05），III组患者PAgT明显低于I组和II组患者（P<0.01）。结论：三七皂甙联合阿司匹林对于抗血小板聚集、颈动脉内膜中层厚度的影响明显优于单用阿司匹林或三七皂甙，且不提高不良反应的发生率，具有良好的疗效性及安全性，为临床抗血栓治疗选择提供依据。
目的：探討三七皂甙聯閤阿司匹林治療腦梗塞的臨床療效及安全性。方法：將84例臨床診斷為腦梗塞的中老年患者隨機分為3組，其中阿司匹林組29例，口服拜阿司匹靈；三七皂甙組27例，口服三七通舒膠囊；三七皂甙聯閤阿司匹林組28例，聯閤服用拜阿司匹靈和三七通舒膠囊。比較三組患者的臨床療效，併分析藥物安全性。結果：三組患者治療後神經功能缺損積分與治療前相比，均顯著降低（P<0.01）。III組與I組和II組相比，積分降低顯著（P<0.05）。與I組相比，II組、III組PT明顯延長，且較I組效果顯著（P<0.01）。在PT-INR比較中，三組患者PT-INR均呈現升高的趨勢（P<0.01），其中以III組效果最佳，與I組和II組相比有顯著性差異（P<0.01）。三組治療後 D-D、PAgT 水平均明顯下降（P<0.01）。I 組患者 PAgT 水平優于 II 組（P<0.05），III組患者PAgT明顯低于I組和II組患者（P<0.01）。結論：三七皂甙聯閤阿司匹林對于抗血小闆聚集、頸動脈內膜中層厚度的影響明顯優于單用阿司匹林或三七皂甙，且不提高不良反應的髮生率，具有良好的療效性及安全性，為臨床抗血栓治療選擇提供依據。
목적：탐토삼칠조대연합아사필림치료뇌경새적림상료효급안전성。방법：장84례림상진단위뇌경새적중노년환자수궤분위3조，기중아사필림조29례，구복배아사필령；삼칠조대조27례，구복삼칠통서효낭；삼칠조대연합아사필림조28례，연합복용배아사필령화삼칠통서효낭。비교삼조환자적림상료효，병분석약물안전성。결과：삼조환자치료후신경공능결손적분여치료전상비，균현저강저（P<0.01）。III조여I조화II조상비，적분강저현저（P<0.05）。여I조상비，II조、III조PT명현연장，차교I조효과현저（P<0.01）。재PT-INR비교중，삼조환자PT-INR균정현승고적추세（P<0.01），기중이III조효과최가，여I조화II조상비유현저성차이（P<0.01）。삼조치료후 D-D、PAgT 수평균명현하강（P<0.01）。I 조환자 PAgT 수평우우 II 조（P<0.05），III조환자PAgT명현저우I조화II조환자（P<0.01）。결론：삼칠조대연합아사필림대우항혈소판취집、경동맥내막중층후도적영향명현우우단용아사필림혹삼칠조대，차불제고불량반응적발생솔，구유량호적료효성급안전성，위림상항혈전치료선택제공의거。
Objective: To discuss the clinical efficacy and safety of the arasaponin plus acetylsalicylic acid on cerebral infarction. Methods: 84 gerontal patients in cerebral infarction were randomly divided into three groups; 29 cases in the acetylsalicylic acid group were given the aspirin treatment; 27 cases in the arasaponin group were given the smooth fluent comfortable panax notoginseng capsule treatment; 28 cases in the arasaponin plus acetylsalicylic acid group were given the aspirin plus the smooth fluent comfortable panax notoginseng capsule treatment. The clinical efficacies in three groups were compared, and analyzed safety of medicine. Results: After treatment, the neurologic deficit score in three groups were decreased obviously (P<0.01). Comparing with the group I and the group II, the deficit score in group III was decreased obviously (P<0.05). Comparing with the group I, PT in the group III was lengthen significantly (P<0.01). PT-INR in three groups were increased (P<0.01), and the effects in the group III was best. There was a significant difference comparing with the group I and the group II (P<0.01). After treatment, D-D, PAgT levels in three groups were significantly decreased (P<0.01). PAgT levels in the group I were better than that in the group II (P<0.05). PAgT levels in the group III were lower than those in the group I and group II significantly (P<0.01). Conclusion: The effects of arasaponin plus acetylsalicylic acid on platelet aggregation and intima-media thickness were better than applying arasaponin or acetylsalicylic acid simply, with less adverse reactions, showing an good efficacy and safety, provided proof for method selection of clinical anti-thrombus treatment.
